Skip to main content

Table 2 Clinical Characteristics of the Sample

From: Correlates of weight gain during long-term risperidone treatment in children and adolescents

Characteristic

Psychiatric Diagnoses, n (%)

Attention Deficit Hyperactivity Disorder

96 (87)

Disruptive Behavior Disorder

100 (91)

Anxiety Disorder

36 (33)

Tic Disorder

24 (22)

Depressive Disorder

12 (11)

Pervasive Developmental Disorder

14 (13)

Psychotic Disorder

1 (1)

Pharmacotherapy

Risperidone Dose, mg/d

1.4 (±1.1)

Risperidone Dose, mg/kg/d

0.03 (±0.02)

Age at Start of Risperidone, yrs

9.1 (±2.8)

Treatment Duration, yrs

2.5 (±1.7)

Psychostimulants, n (%)

78 (71)

Psychostimulants Dose, mg/d a

59.2 (±28.6)

Psychostimulants Dose, mg/kg/d a

1.35 (±0.70)

Psychostimulants Treatment Duration, yrs

4.8 (±2.7)

SSRIs, n (%)

55 (50)

  Fluoxetine

21 (19)

  Sertraline

16 (15)

  Citalopram/Escitalopram

18 (16)

SSRI Dose, unit per day b

1.30 (±0.83)

SSRI Treatment Duration, yrs

2.6 (±2.1)

α2-agonists, n (%)

35 (32)

  1. a All dosages of psychostimulants were expressed in methylphenidate equivalents for amphetamines (x 2) [33].
  2. b One SSRI unit is equivalent to a daily dose of 10 mg of escitalopram, 20 mg of fluoxetine, citalopram, or paroxetine, and 50 mg of sertraline or fluvoxamine [25].